Full-Time
Associate Director
Supply Chain Account Management, ANZ
Alexion
5,001-10,000 employees
Global biopharmaceuticals focusing on rare diseases
No salary listed
New South Wales, Australia
In Person
Bachelor's
 Operations & Logistics (1) |
|---|
Get referred to Alexion
See people who can refer or advise you
- A degree in Supply Chain, Business, Science, or a related field; equivalent experience is also considered.
- Strong experience across demand planning or integrated business planning, supply chain operations, and distribution and logistics management.
- Experience working in complex, high-variability demand environments.
- Proven ability to influence cross-functional stakeholders in a matrix environment and lead structured decision-making.
- Experience managing third-party logistics providers, specialty distribution channels, or regulated logistics networks.
- Demonstrated agility and patient-centred focus, including the ability to deliver time-critical supply outcomes outside normal business hours when required.
- Willingness and ability to work closely with global stakeholders, including regular communication and collaboration with teams based in Dublin, Ireland, to support supply planning and operational priorities.
- Lead the Australia and New Zealand sales and operations planning and Integrated Business Planning process, driving cross-functional alignment and informed business decisions.
- Translate patient and market insights into demand and supply plans that support continuity of supply and patient access.
- Facilitate governance forums and leadership reviews, providing clear insights to support decision-making.
- Lead distribution, inventory, and logistics performance across Australia and New Zealand, ensuring compliant, reliable, and patient-focused delivery.
- Act as the single point of contact for supply chain, distribution, and logistics matters across Australia and New Zealand, building relationships with Commercial, Medical, Market Access, Finance, Regulatory, and Quality teams.
- Lead supply chain readiness for new product launches, indications, product transitions, and lifecycle management activities.
- Monitor and improve forecast accuracy, service levels, and supply reliability, proactively identifying and mitigating risks.
- Drive continuous improvement across planning, data quality, distribution performance, and digital capabilities.
- Champion the adoption of artificial-intelligence-enabled solutions to improve decision-making, operational agility, and productivity across market operations.
- Experience in rare disease, specialty care, or biopharmaceutical environments.
- Experience managing product launches with complex distribution requirements.
- Familiarity with SAP, Integrated Business Planning, or other planning systems.
- Understanding of Good Distribution Practice, cold chain, and patient-critical supply chains.
Alexion focuses on discovering, developing, and selling therapies for rare and ultra-rare diseases by targeting the complement system. Its drugs, such as Soliris and Ultomiris, inhibit C5 to block inflammatory cascades, while Strensiq and Kanuma treat metabolic and lysosomal disorders. The company combines in-house R&D with acquisitions to expand its portfolio and leverages AstraZeneca’s global scale to reach patients. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to international markets at premium pricing.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Boston, Massachusetts
Founded
1992
Get referred to Alexion
See people who can refer or advise you
Simplify's Take
What believers are saying
- AstraZeneca's July 2026 half-year revenue rose 9%, driven partly by Alexion's rare-disease growth.
- Ultomiris gained FDA Priority Review on June 15, 2026 for IgAN, with Q4 2026 decision.
- Koselugo's November 2025 adult NF1 approval and ALXN2220 phase 3 expand the pipeline.
What critics are saying
- EmblemHealth's April 2025 Soliris antitrust suit targets patent settlements and biosimilar delays.
- Soliris faces biosimilar erosion after March 2025, while Ultomiris still depends on C5-franchise switching.
- Ultomiris carries meningococcal boxed warnings; a single fatal infection can trigger litigation and prescribing pullback.
What makes Alexion unique
- Alexion pioneered complement biology, turning C5 inhibition into approved medicines since Soliris, 2007.
- Ultomiris, Soliris, Strensiq, and Koselugo span hematology, nephrology, endocrinology, and oncology-adjacent rare diseases.
- AstraZeneca's 2021 acquisition gives Alexion global commercialization scale and deeper trial funding.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Stock Options
Company Equity
401(k) Retirement Plan
Mental Health Support
Wellness Program
Gym Membership
Phone/Internet Stipend
Home Office Stipend
Professional Development Budget
Conference Attendance Budget
Training Programs
Tuition Reimbursement
Professional Certification Support
Mentorship Program
Parental Leave
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Childcare Support
Elder Care Support
Relocation Assistance
Employee Referral Bonus
Meal Benefits
Commuter Benefits
Legal Services
Employee Discounts
Company Social Events
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 1%"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."
Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases, has, in collaboration with its partner Alexion, advanced its drug candidate ALXN2220 into phase 3. This marks a significant step in the company’s journey to addressing the serious clinical condition ATTR-CM. Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic clinical condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis. Despite recent advances in slowing disease progression, there is currently no treatment available to deplete cardiac ATTR amyloid and revert cardiac dysfunction. Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and ATTR cardiomyopathy, is currently testing a drug candidate, ALXN2220 (formerly NI006), a human antibody targeting ATTR Cardiomyopathy. In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, for ALXN2220. Neurimmune is responsible for completion of the phase 1b clinical study on behalf of Alexion, with Alexion incurring certain trial costs. Aside from the phase 1b trial, Alexion is responsible for further clinical development, manufacturing, and commercialization as ALXN2220. The two companies have now initiated the phase 3 of the DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 for the treatment of ATTR-CM
WILMINGTON, Del.--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).1 VOYDEYA is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant EVH while treated with a C5 inhibitor.2,3. The approval by the US Food and Drug Administration (FDA) was based on positive results from the pivotal ALPHA Phase III trial. Results from the 12-week primary evaluation period of the trial were published in The Lancet Haematology.2. Bart Scott, MD, Professor, Division of Hematology and Oncology at the University of Washington Medical Center, and Professor, Clinical Research Division at Fred Hutchinson Cancer Center, said: “The approval of VOYDEYA offers this small subset of PNH patients an add-on therapy designed to address EVH, while maintaining disease control with ULTOMIRIS or SOLIRIS. Terminal complement inhibition with ULTOMIRIS can address the life-threatening complications of PNH, building on the efficacy and safety of SOLIRIS established over nearly 20 years.”
WILMINGTON, Del.--(BUSINESS WIRE)--ULTOMIRIS® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1. The approval by the US Food and Drug Administration (FDA) was based on positive results from the CHAMPION-NMOSD Phase III trial, which were published in the Annals of Neurology.2 In the trial, ULTOMIRIS was compared to an external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial. ULTOMIRIS met the primary endpoint of time to first on-trial relapse as confirmed by an independent adjudication committee. Zero relapses were observed among ULTOMIRIS patients with a median treatment duration of 73 weeks (relapse risk reduction: 98.6%, hazard ratio (95% CI): 0.014 (0.000, 0.103), p0.0001).2
Sebelipase alfa (Kanuma®▼) recommended by NICE as the first treatment for infants with ultra-rare Wolman Disease. . Kanuma, an enzyme replacement therapy, is the first medicine to be recommended for this life-threatening condition in infants under two years old